The purpose of ordering for ferrous sulfate. Case summary: J.T. is a 37-year-old homemaker who is receiving the second round of chemotherapy for ovarian cancer. Chemotherapeutic drugs lead to adverse effects in the blood cell components due to the suppression in the bone marrow. Two weeks later, J.T.’s hemoglobin level decreased to 7.9 g/dL and her hematocrit level decreased to 28.5% from her pretherapy levels. She had received the following orders: ferrous sulfate 300 mg by mouth daily, and epoetin alfa (Epogen) 150 units/kg subcutaneously three times a week.

Question

Want to see the full answer?

Answer 1

Question

Chapter 54, Problem 1CS

(1)

Summary Introduction

To determine:

The purpose of ordering for ferrous sulfate.

Case summary:

J.T. is a 37-year-old homemaker who is receiving the second round of chemotherapy for ovarian cancer. Chemotherapeutic drugs lead to adverse effects in the blood cell components due to the suppression in the bone marrow. Two weeks later, J.T.’s hemoglobin level decreased to 7.9 g/dL and her hematocrit level decreased to 28.5% from her pretherapy levels. She had received the following orders: ferrous sulfate 300 mg by mouth daily, and epoetin alfa (Epogen) 150 units/kg subcutaneously three times a week.

(2)

Summary Introduction

To explain:

Before beginning the epoetin therapy, the nurse will assess for what condition?

Case summary:

J.T. is a 37-year-old homemaker who is receiving the second round of chemotherapy for ovarian cancer. Chemotherapeutic drugs lead to adverse effects in the blood cell components due to the suppression in the bone marrow. Two weeks later, J.T.’s hemoglobin level decreased to 7.9 g/dL and her hematocrit level decreased to 28.5% from her pretherapy levels. She had received the following orders: ferrous sulfate 300 mg by mouth daily, and epoetin alfa (Epogen) 150 units/kg subcutaneously three times a week.

(3)

Summary Introduction

To determine:

What is the most concerned assessment finding that the nurse needs to monitor during this therapy?

Case summary:

J.T. is a 37-year-old homemaker who is receiving the second round of chemotherapy for ovarian cancer. Chemotherapeutic drugs lead to adverse effects in the blood cell components due to the suppression in the bone marrow. Two weeks later, J.T.’s hemoglobin level decreased to 7.9 g/dL and her hematocrit level decreased to 28.5% from her pretherapy levels. She had received the following orders: ferrous sulfate 300 mg by mouth daily, and epoetin alfa (Epogen) 150 units/kg subcutaneously three times a week.

(4)

Summary Introduction

To explain:

After 5 weeks, J.T’s hemoglobin level is 11.4 g/dL and hematocrit is 33%. The next dose of the drug epoetin alfa (Epogen) is due today and what action will the nurse take?

Case summary:

J.T. is a 37-year-old homemaker who is receiving the second round of chemotherapy for ovarian cancer. Chemotherapeutic drugs lead to adverse effects in the blood cell components due to the suppression in the bone marrow. Two weeks later, J.T.’s hemoglobin level decreased to 7.9 g/dL and her hematocrit level decreased to 28.5% from her pretherapy levels. She had received the following orders: ferrous sulfate 300 mg by mouth daily, and epoetin alfa (Epogen) 150 units/kg subcutaneously three times a week.

Expert Solution & Answer

Want to see the full answer?

Check out a sample textbook solution

See solution

Students have asked these similar questions

A 65 year old male with a small bowel obstruction is to be started on TPN. He is 5’ 9” and weighs 70 kg. 3.1 What is his kcal requirements using Mifflin St Jeor equation? Assume an activity factor of 1.2. 1770 kcal 1980 kcal 2020 kcal 2080 kcal 3.2 What is his fluid requirements (ml)? 2000 ml 2100 ml 2200 ml 2300 ml 3.3 The patient has just undergone a small bowel resection. His albumin dropped to 2.2. He has no significant past medical history except for a minor bicycle accident when he was 10 years old. How many grams of protein will this patient require based on your assessment? 105 – 126 g/day 110 – 130 g/day 84 – 105 g/day 110 – 180 g/day

Two kind verb

Nutrition Internvention

Answer 2

Question

Chapter 54, Problem 1CS

(1)

Summary Introduction

To determine:

The purpose of ordering for ferrous sulfate.

Case summary:

J.T. is a 37-year-old homemaker who is receiving the second round of chemotherapy for ovarian cancer. Chemotherapeutic drugs lead to adverse effects in the blood cell components due to the suppression in the bone marrow. Two weeks later, J.T.’s hemoglobin level decreased to 7.9 g/dL and her hematocrit level decreased to 28.5% from her pretherapy levels. She had received the following orders: ferrous sulfate 300 mg by mouth daily, and epoetin alfa (Epogen) 150 units/kg subcutaneously three times a week.

(2)

Summary Introduction

To explain:

Before beginning the epoetin therapy, the nurse will assess for what condition?

Case summary:

J.T. is a 37-year-old homemaker who is receiving the second round of chemotherapy for ovarian cancer. Chemotherapeutic drugs lead to adverse effects in the blood cell components due to the suppression in the bone marrow. Two weeks later, J.T.’s hemoglobin level decreased to 7.9 g/dL and her hematocrit level decreased to 28.5% from her pretherapy levels. She had received the following orders: ferrous sulfate 300 mg by mouth daily, and epoetin alfa (Epogen) 150 units/kg subcutaneously three times a week.

(3)

Summary Introduction

To determine:

What is the most concerned assessment finding that the nurse needs to monitor during this therapy?

Case summary:

J.T. is a 37-year-old homemaker who is receiving the second round of chemotherapy for ovarian cancer. Chemotherapeutic drugs lead to adverse effects in the blood cell components due to the suppression in the bone marrow. Two weeks later, J.T.’s hemoglobin level decreased to 7.9 g/dL and her hematocrit level decreased to 28.5% from her pretherapy levels. She had received the following orders: ferrous sulfate 300 mg by mouth daily, and epoetin alfa (Epogen) 150 units/kg subcutaneously three times a week.

(4)

Summary Introduction

To explain:

After 5 weeks, J.T’s hemoglobin level is 11.4 g/dL and hematocrit is 33%. The next dose of the drug epoetin alfa (Epogen) is due today and what action will the nurse take?

Case summary:

J.T. is a 37-year-old homemaker who is receiving the second round of chemotherapy for ovarian cancer. Chemotherapeutic drugs lead to adverse effects in the blood cell components due to the suppression in the bone marrow. Two weeks later, J.T.’s hemoglobin level decreased to 7.9 g/dL and her hematocrit level decreased to 28.5% from her pretherapy levels. She had received the following orders: ferrous sulfate 300 mg by mouth daily, and epoetin alfa (Epogen) 150 units/kg subcutaneously three times a week.

Expert Solution & Answer

Want to see the full answer?

Check out a sample textbook solution

See solution

Answer 3

Question

Chapter 54, Problem 1CS

(1)

Summary Introduction

To determine:

The purpose of ordering for ferrous sulfate.

Case summary:

J.T. is a 37-year-old homemaker who is receiving the second round of chemotherapy for ovarian cancer. Chemotherapeutic drugs lead to adverse effects in the blood cell components due to the suppression in the bone marrow. Two weeks later, J.T.’s hemoglobin level decreased to 7.9 g/dL and her hematocrit level decreased to 28.5% from her pretherapy levels. She had received the following orders: ferrous sulfate 300 mg by mouth daily, and epoetin alfa (Epogen) 150 units/kg subcutaneously three times a week.

(2)

Summary Introduction

To explain:

Before beginning the epoetin therapy, the nurse will assess for what condition?

Case summary:

J.T. is a 37-year-old homemaker who is receiving the second round of chemotherapy for ovarian cancer. Chemotherapeutic drugs lead to adverse effects in the blood cell components due to the suppression in the bone marrow. Two weeks later, J.T.’s hemoglobin level decreased to 7.9 g/dL and her hematocrit level decreased to 28.5% from her pretherapy levels. She had received the following orders: ferrous sulfate 300 mg by mouth daily, and epoetin alfa (Epogen) 150 units/kg subcutaneously three times a week.

(3)

Summary Introduction

To determine:

What is the most concerned assessment finding that the nurse needs to monitor during this therapy?

Case summary:

J.T. is a 37-year-old homemaker who is receiving the second round of chemotherapy for ovarian cancer. Chemotherapeutic drugs lead to adverse effects in the blood cell components due to the suppression in the bone marrow. Two weeks later, J.T.’s hemoglobin level decreased to 7.9 g/dL and her hematocrit level decreased to 28.5% from her pretherapy levels. She had received the following orders: ferrous sulfate 300 mg by mouth daily, and epoetin alfa (Epogen) 150 units/kg subcutaneously three times a week.

(4)

Summary Introduction

To explain:

After 5 weeks, J.T’s hemoglobin level is 11.4 g/dL and hematocrit is 33%. The next dose of the drug epoetin alfa (Epogen) is due today and what action will the nurse take?

Case summary:

J.T. is a 37-year-old homemaker who is receiving the second round of chemotherapy for ovarian cancer. Chemotherapeutic drugs lead to adverse effects in the blood cell components due to the suppression in the bone marrow. Two weeks later, J.T.’s hemoglobin level decreased to 7.9 g/dL and her hematocrit level decreased to 28.5% from her pretherapy levels. She had received the following orders: ferrous sulfate 300 mg by mouth daily, and epoetin alfa (Epogen) 150 units/kg subcutaneously three times a week.

Expert Solution & Answer

Want to see the full answer?

Check out a sample textbook solution

See solution

Answer 4

Question

Chapter 54, Problem 1CS

(1)

Summary Introduction

To determine:

The purpose of ordering for ferrous sulfate.

Case summary:

J.T. is a 37-year-old homemaker who is receiving the second round of chemotherapy for ovarian cancer. Chemotherapeutic drugs lead to adverse effects in the blood cell components due to the suppression in the bone marrow. Two weeks later, J.T.’s hemoglobin level decreased to 7.9 g/dL and her hematocrit level decreased to 28.5% from her pretherapy levels. She had received the following orders: ferrous sulfate 300 mg by mouth daily, and epoetin alfa (Epogen) 150 units/kg subcutaneously three times a week.

(2)

Summary Introduction

To explain:

Before beginning the epoetin therapy, the nurse will assess for what condition?

Case summary:

J.T. is a 37-year-old homemaker who is receiving the second round of chemotherapy for ovarian cancer. Chemotherapeutic drugs lead to adverse effects in the blood cell components due to the suppression in the bone marrow. Two weeks later, J.T.’s hemoglobin level decreased to 7.9 g/dL and her hematocrit level decreased to 28.5% from her pretherapy levels. She had received the following orders: ferrous sulfate 300 mg by mouth daily, and epoetin alfa (Epogen) 150 units/kg subcutaneously three times a week.

(3)

Summary Introduction

To determine:

What is the most concerned assessment finding that the nurse needs to monitor during this therapy?

Case summary:

J.T. is a 37-year-old homemaker who is receiving the second round of chemotherapy for ovarian cancer. Chemotherapeutic drugs lead to adverse effects in the blood cell components due to the suppression in the bone marrow. Two weeks later, J.T.’s hemoglobin level decreased to 7.9 g/dL and her hematocrit level decreased to 28.5% from her pretherapy levels. She had received the following orders: ferrous sulfate 300 mg by mouth daily, and epoetin alfa (Epogen) 150 units/kg subcutaneously three times a week.

(4)

Summary Introduction

To explain:

After 5 weeks, J.T’s hemoglobin level is 11.4 g/dL and hematocrit is 33%. The next dose of the drug epoetin alfa (Epogen) is due today and what action will the nurse take?

Case summary:

J.T. is a 37-year-old homemaker who is receiving the second round of chemotherapy for ovarian cancer. Chemotherapeutic drugs lead to adverse effects in the blood cell components due to the suppression in the bone marrow. Two weeks later, J.T.’s hemoglobin level decreased to 7.9 g/dL and her hematocrit level decreased to 28.5% from her pretherapy levels. She had received the following orders: ferrous sulfate 300 mg by mouth daily, and epoetin alfa (Epogen) 150 units/kg subcutaneously three times a week.

Expert Solution & Answer

Want to see the full answer?

Check out a sample textbook solution

See solution

Answer 5

Chapter 54, Problem 1CS

(1)

Summary Introduction

To determine:

The purpose of ordering for ferrous sulfate.

Case summary:

J.T. is a 37-year-old homemaker who is receiving the second round of chemotherapy for ovarian cancer. Chemotherapeutic drugs lead to adverse effects in the blood cell components due to the suppression in the bone marrow. Two weeks later, J.T.’s hemoglobin level decreased to 7.9 g/dL and her hematocrit level decreased to 28.5% from her pretherapy levels. She had received the following orders: ferrous sulfate 300 mg by mouth daily, and epoetin alfa (Epogen) 150 units/kg subcutaneously three times a week.

(2)

Summary Introduction

To explain:

Before beginning the epoetin therapy, the nurse will assess for what condition?

Case summary:

J.T. is a 37-year-old homemaker who is receiving the second round of chemotherapy for ovarian cancer. Chemotherapeutic drugs lead to adverse effects in the blood cell components due to the suppression in the bone marrow. Two weeks later, J.T.’s hemoglobin level decreased to 7.9 g/dL and her hematocrit level decreased to 28.5% from her pretherapy levels. She had received the following orders: ferrous sulfate 300 mg by mouth daily, and epoetin alfa (Epogen) 150 units/kg subcutaneously three times a week.

(3)

Summary Introduction

To determine:

What is the most concerned assessment finding that the nurse needs to monitor during this therapy?

Case summary:

J.T. is a 37-year-old homemaker who is receiving the second round of chemotherapy for ovarian cancer. Chemotherapeutic drugs lead to adverse effects in the blood cell components due to the suppression in the bone marrow. Two weeks later, J.T.’s hemoglobin level decreased to 7.9 g/dL and her hematocrit level decreased to 28.5% from her pretherapy levels. She had received the following orders: ferrous sulfate 300 mg by mouth daily, and epoetin alfa (Epogen) 150 units/kg subcutaneously three times a week.

(4)

Summary Introduction

To explain:

After 5 weeks, J.T’s hemoglobin level is 11.4 g/dL and hematocrit is 33%. The next dose of the drug epoetin alfa (Epogen) is due today and what action will the nurse take?

Case summary:

J.T. is a 37-year-old homemaker who is receiving the second round of chemotherapy for ovarian cancer. Chemotherapeutic drugs lead to adverse effects in the blood cell components due to the suppression in the bone marrow. Two weeks later, J.T.’s hemoglobin level decreased to 7.9 g/dL and her hematocrit level decreased to 28.5% from her pretherapy levels. She had received the following orders: ferrous sulfate 300 mg by mouth daily, and epoetin alfa (Epogen) 150 units/kg subcutaneously three times a week.

Answer 6

Chapter 54, Problem 1CS

(1)

Summary Introduction

To determine:

The purpose of ordering for ferrous sulfate.

Case summary:

J.T. is a 37-year-old homemaker who is receiving the second round of chemotherapy for ovarian cancer. Chemotherapeutic drugs lead to adverse effects in the blood cell components due to the suppression in the bone marrow. Two weeks later, J.T.’s hemoglobin level decreased to 7.9 g/dL and her hematocrit level decreased to 28.5% from her pretherapy levels. She had received the following orders: ferrous sulfate 300 mg by mouth daily, and epoetin alfa (Epogen) 150 units/kg subcutaneously three times a week.

Answer 7

Chapter 54, Problem 1CS

(1)

Summary Introduction

To determine:

The purpose of ordering for ferrous sulfate.

Case summary:

J.T. is a 37-year-old homemaker who is receiving the second round of chemotherapy for ovarian cancer. Chemotherapeutic drugs lead to adverse effects in the blood cell components due to the suppression in the bone marrow. Two weeks later, J.T.’s hemoglobin level decreased to 7.9 g/dL and her hematocrit level decreased to 28.5% from her pretherapy levels. She had received the following orders: ferrous sulfate 300 mg by mouth daily, and epoetin alfa (Epogen) 150 units/kg subcutaneously three times a week.

Answer 8

(2)

Summary Introduction

To explain:

Before beginning the epoetin therapy, the nurse will assess for what condition?

Case summary:

J.T. is a 37-year-old homemaker who is receiving the second round of chemotherapy for ovarian cancer. Chemotherapeutic drugs lead to adverse effects in the blood cell components due to the suppression in the bone marrow. Two weeks later, J.T.’s hemoglobin level decreased to 7.9 g/dL and her hematocrit level decreased to 28.5% from her pretherapy levels. She had received the following orders: ferrous sulfate 300 mg by mouth daily, and epoetin alfa (Epogen) 150 units/kg subcutaneously three times a week.

Answer 9

(2)

Summary Introduction

To explain:

Before beginning the epoetin therapy, the nurse will assess for what condition?

Case summary:

J.T. is a 37-year-old homemaker who is receiving the second round of chemotherapy for ovarian cancer. Chemotherapeutic drugs lead to adverse effects in the blood cell components due to the suppression in the bone marrow. Two weeks later, J.T.’s hemoglobin level decreased to 7.9 g/dL and her hematocrit level decreased to 28.5% from her pretherapy levels. She had received the following orders: ferrous sulfate 300 mg by mouth daily, and epoetin alfa (Epogen) 150 units/kg subcutaneously three times a week.

Answer 10

(3)

Summary Introduction

To determine:

What is the most concerned assessment finding that the nurse needs to monitor during this therapy?

Case summary:

J.T. is a 37-year-old homemaker who is receiving the second round of chemotherapy for ovarian cancer. Chemotherapeutic drugs lead to adverse effects in the blood cell components due to the suppression in the bone marrow. Two weeks later, J.T.’s hemoglobin level decreased to 7.9 g/dL and her hematocrit level decreased to 28.5% from her pretherapy levels. She had received the following orders: ferrous sulfate 300 mg by mouth daily, and epoetin alfa (Epogen) 150 units/kg subcutaneously three times a week.

Answer 11

(3)

Summary Introduction

To determine:

What is the most concerned assessment finding that the nurse needs to monitor during this therapy?

Case summary:

J.T. is a 37-year-old homemaker who is receiving the second round of chemotherapy for ovarian cancer. Chemotherapeutic drugs lead to adverse effects in the blood cell components due to the suppression in the bone marrow. Two weeks later, J.T.’s hemoglobin level decreased to 7.9 g/dL and her hematocrit level decreased to 28.5% from her pretherapy levels. She had received the following orders: ferrous sulfate 300 mg by mouth daily, and epoetin alfa (Epogen) 150 units/kg subcutaneously three times a week.

Answer 12

(4)

Summary Introduction

To explain:

After 5 weeks, J.T’s hemoglobin level is 11.4 g/dL and hematocrit is 33%. The next dose of the drug epoetin alfa (Epogen) is due today and what action will the nurse take?

Case summary:

J.T. is a 37-year-old homemaker who is receiving the second round of chemotherapy for ovarian cancer. Chemotherapeutic drugs lead to adverse effects in the blood cell components due to the suppression in the bone marrow. Two weeks later, J.T.’s hemoglobin level decreased to 7.9 g/dL and her hematocrit level decreased to 28.5% from her pretherapy levels. She had received the following orders: ferrous sulfate 300 mg by mouth daily, and epoetin alfa (Epogen) 150 units/kg subcutaneously three times a week.

Answer 13

(4)

Summary Introduction

To explain:

After 5 weeks, J.T’s hemoglobin level is 11.4 g/dL and hematocrit is 33%. The next dose of the drug epoetin alfa (Epogen) is due today and what action will the nurse take?

Case summary:

J.T. is a 37-year-old homemaker who is receiving the second round of chemotherapy for ovarian cancer. Chemotherapeutic drugs lead to adverse effects in the blood cell components due to the suppression in the bone marrow. Two weeks later, J.T.’s hemoglobin level decreased to 7.9 g/dL and her hematocrit level decreased to 28.5% from her pretherapy levels. She had received the following orders: ferrous sulfate 300 mg by mouth daily, and epoetin alfa (Epogen) 150 units/kg subcutaneously three times a week.

Answer 14

Expert Solution & Answer

Answer 15

Expert Solution & Answer

Answer 16

Want to see the full answer?

Check out a sample textbook solution

See solution

Answer 17

Ch. 54 - Prob. 1O Ch. 54 - Prob. 2O Ch. 54 - Prob. 3O Ch. 54 - Prob. 4O Ch. 54 - Prob. 1CS Ch. 54 - Prob. 1NERQ Ch. 54 - Prob. 2NERQ Ch. 54 - Prob. 3NERQ Ch. 54 - Prob. 4NERQ Ch. 54 - Prob. 5NERQ

Want to see the full answer?

Chapter 54 Solutions